JPRN-UMIN000030456
Recruiting
未知
Study on drug blood concentration, effectiveness, safety, and drug tolerance using residual samples of permission system and notification type antimicrobial drug - Specific antibacterial drug residual sample PK PD study
Conditionsinfectious disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- infectious disease
- Sponsor
- Keio University Hospital
- Enrollment
- 3250
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.subject licensing system and notification system Patients with a history of allergy to antibiotic drugs 2\.Patients who are clinically judged to be unlikely to expect the efficacy of this drug in infections caused by this drug insensitive pathogen or resistant strain 3\.Other patients judged inappropriate as subject of this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Blood concentration and pharmacokinetic analysis of propofol following administration of single induction dose in small childreChildren scheduled for elective surgeryTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]EUCTR2016-002323-28-BEniversitair Ziekenhuis Brussel120
Completed
Not Applicable
The examination of concentration of drug in tissues from the knee osteoarthritis patients who use the Esflurbiprofen tape or FlurbiprofeosteoarthritisJPRN-UMIN000024789Tokyo Medical and Dental University14
Recruiting
Not Applicable
Study of Clinical outcomes and serum concentration of Meropenem in acute kidney injuryAcute kidney disease.Acute kidney failureIRCT20160412027346N5Shahid Beheshti University of Medical Sciences34
Not yet recruiting
Phase 1
Clinical study of Darvyadi Granules in Iron Deficiency Anaemia.Health Condition 1: D508- Other iron deficiency anemiasHealth Condition 2: D508- Other iron deficiency anemiasCTRI/2020/04/024459Parul University
Active, not recruiting
Not Applicable
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-000535-36-CZAbbott GmbH & Co. KG100